The role of GATA2 in lethal prostate cancer aggressiveness

被引:0
|
作者
Veronica Rodriguez-Bravo
Marc Carceles-Cordon
Yujin Hoshida
Carlos Cordon-Cardo
Matthew D. Galsky
Josep Domingo-Domenech
机构
[1] Icahn School of Medicine at Mount Sinai,Department of Pathology
[2] Icahn School of Medicine at Mount Sinai,Department of Oncological Sciences
[3] Icahn School of Medicine at Mount Sinai,Department of Hematology and Oncology
来源
Nature Reviews Urology | 2017年 / 14卷
关键词
D O I
暂无
中图分类号
学科分类号
摘要
Endothelial transcription factor GATA-2 (GATA2) is a pioneer, master-regulator, transcription factor that binds DNA regions of closed chromatin, causing opening and facilitating subsequent hierarchical binding of other regulators that activate transcriptionGATA2 is crucial for the development of the genitourinary system and might be a lineage marker of mouse and human prostate tissueGATA2 drives androgen-responsive gene expression and contributes to prostate cancer metastasis by increasing tumour cell motility and invasiveness in early stages of the disease, through its pioneer transcription factor functionGATA2 is important in prostate cancer progression to an androgen-refractory state and regulates an androgen-independent signalling network in late stages of the diseasePreclinical experimental data have demonstrated the utility of inhibiting GATA2 through targeting its upstream regulators, post-translational modifications, and downstream effectorsIntegrating GATA2 inhibition into the therapeutic landscape of prostate cancer will require the development of precise predictive assays and identification of the most effective therapeutic combination
引用
收藏
页码:38 / 48
页数:10
相关论文
共 50 条
  • [1] The role of GATA2 in lethal prostate cancer aggressiveness
    Rodriguez-Bravo, Veronica
    Carceles-Cordon, Marc
    Hoshida, Yujin
    Cordon-Cardo, Carlos
    Galsky, Matthew D.
    Domingo-Domenech, Josep
    NATURE REVIEWS UROLOGY, 2017, 14 (01) : 38 - 48
  • [2] A targetable GATA2-IGF2 axis confers aggressiveness in lethal prostate cancer
    Vidal, Samuel J.
    Rodriguez-Bravo, Veronica
    Quinn, Aidan
    Williams, Estrelania
    de la Iglesia-Vicente, Janis
    Sun, Xiaochen
    Chen, Xintong
    Hoshida, Yujin
    Cordon-Cardo, Carlos
    Domingo-Domenech, Josep
    CANCER RESEARCH, 2015, 75
  • [3] A Targetable GATA2-IGF2 Axis Confers Aggressiveness in Lethal Prostate Cancer
    Vidal, Samuel J.
    Rodriguez-Bravo, Veronica
    Quinn, S. Aidan
    Rodriguez-Barrueco, Ruth
    Lujambio, Amaia
    Williams, Estrelania
    Sun, Xiaochen
    de la Iglesia-Vicente, Janis
    Lee, Albert
    Readhead, Ben
    Chen, Xintong
    Galsky, Matthew
    Esteve, Berta
    Petrylak, Daniel P.
    Dudley, Joel T.
    Rabadan, Raul
    Silva, Jose M.
    Hoshida, Yujin
    Lowe, Scott W.
    Cordon-Cardo, Carlos
    Domingo-Domenech, Josep
    CANCER CELL, 2015, 27 (02) : 223 - 239
  • [4] GATA2: Potential role as a prostate cancer metastasis-driving gene
    Chiang, Yan Ting
    Wang, Kendric
    Crea, Francesco
    Collins, Colin
    Gout, Peter
    Wang, Yuzhuo
    CANCER RESEARCH, 2014, 74 (19)
  • [5] GATA2 as a potential metastasis-driving gene in prostate cancer
    Chiang, Yan Ting
    Wang, Kendric
    Fazli, Ladan
    Qi, Robert Z.
    Gleave, Martin E.
    Collins, Colin C.
    Gout, Peter W.
    Wang, Yuzhuo
    ONCOTARGET, 2014, 5 (02) : 451 - 461
  • [6] Inhibition of GATA2 in prostate cancer by a clinically available small molecule
    Kaochar, Salma
    Rusin, Aleksandra
    Foley, Christopher
    Rajapakshe, Kimal
    Robertson, Matthew
    Skapura, Darlene
    Mason, Cammy
    De Ruiz, Karen Berman
    Tyryshkin, Alexey Mikhailovich
    Deng, Jenny
    Shin, Jin Na
    Fiskus, Warren
    Dong, Jianrong
    Huang, Shixia
    Navone, Nora M.
    Davis, Christel M.
    Ehli, Erik A.
    Coarfa, Cristian
    Mitsiades, Nicholas
    ENDOCRINE-RELATED CANCER, 2022, 29 (01) : 15 - 31
  • [7] Aberrant GATA2 epigenetic dysregulation induces a GATA2/GATA6 switch in human gastric cancer
    S H Song
    M S Jeon
    J W Nam
    J K Kang
    Y J Lee
    J Y Kang
    H P Kim
    S W Han
    G H Kang
    T Y Kim
    Oncogene, 2018, 37 : 993 - 1004
  • [8] GATA2 a novel potential therapeutic target for treatment of neuroendocrine prostate cancer
    Dash, Amit K.
    Echartea, Maria Elisa Ruiz
    Skapura, Darlene
    de Ruiz, Karen Berman
    Deng, Jenny Jianmin
    Coarfa, Cristian
    Kaochar, Salma
    CANCER RESEARCH, 2023, 83 (07)
  • [9] Aberrant GATA2 epigenetic dysregulation induces a GATA2/GATA6 switch in human gastric cancer
    Song, S. H.
    Jeon, M. S.
    Nam, J. W.
    Kang, J. K.
    Lee, Y. J.
    Kang, J. Y.
    Kim, H. P.
    Han, S. W.
    Kang, G. H.
    Kim, T. Y.
    ONCOGENE, 2018, 37 (08) : 993 - 1004
  • [10] The Role of GATA2 in Drug Resistance in AML
    Alikarami, Fatemeh
    Riedel, Simone S.
    Li, Qinglan
    Chen, Changya
    Yamauchi, Taylor
    Danis, Etienne
    Tan, Kai
    Wan, Liling
    Neff, Tobias
    Bernt, Kathrin M.
    BLOOD, 2022, 140